• Mira Dreesen, Veerle Foulon, Martin Hiele, Kris Vanhaecht, Lutgart De Pourcq, Loris Pironi, André Van Gossum, Jann Arends, Cristina Cuerda, Paul Thul, Frederico Bozzetti, and Ludo Willems.
• Pharmacy Department, University Hospitals Leuven, & Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. mira.dreesen@uzleuven.be
• Support Care Cancer. 2013 May 1;21(5):1373-81.

PurposeClear recommendations on how to guide patients with cancer on home parenteral nutrition (HPN) are lacking as the use of HPN in this population remains a controversial issue. Therefore, the aims of this study were to rank treatment recommendations and main outcome indicators to ensure high-quality care and to indicate differences in care concerning benign versus malignant patients.MethodsTreatment recommendations, identified from published guidelines, were used as a starting point for a two-round Delphi approach. Comments and additional interventions proposed in the first round were reevaluated in the second round. Ordinal logistic regression with SPSS 2.0 was used to identify differences in care concerning benign versus malignant patients.ResultsTwenty-seven experts from five European countries completed two Delphi rounds. After the second Delphi round, the top three most important outcome indicators were (1) quality of life (QoL), (2) incidence of hospital readmission and (3) incidence of catheter-related infections. Forty-two interventions were considered as important for quality of care (28/42 based on published guidelines; 14/42 newly suggested by Delphi panel). The topics 'Liver disease' and 'Metabolic bone disease' were considered less important for cancer patients, together with use of infusion pumps (p = 0.004) and monitoring of vitamins and trace elements (p = 0.000). Monitoring of QoL is considered more important for cancer patients (p = 0.03).ConclusionUsing a two-round Delphi approach, we developed a minimal set of 42 interventions that may be used to determine quality of care in HPN patients with malignancies. This set of interventions differs from a similar set developed for benign patients.

23 keywords...

hide…